| Autor: |
McGuire, A., Dreyer, A. M., Hoot, S., Lippy, A., Stuart, A., Cohen, K. W., Jardine, J., Menis, S., Scheid, J. F., West, A. P., Jr., Schief, W. R., Stamatatos, L. |
| Jazyk: |
angličtina |
| Rok vydání: |
2013 |
| Popis: |
The recent RV144 trial showed ~30% efficacy. Although the protection was modest, the trial indicated for the first time that a vaccine against HIV is possible. Immune correlate analysis suggests that the observed protection was due to non-neutralizing antibody responses. This efficacy might be improved if a vaccine could elicit broadly neutralizing antibodies (bNAbs). Of particular interest for vaccine design are the potent VRC01- class bNAbs targeting CD4 binding site on Env. Unfortunately, a number of studies have demonstrated that recombinant Env proteins do not bind germline-reverted VRC01 class Abs, indicating that current vaccine strategies using recombinant Env are unable to activate progenitor B cells that ultimately give rise to VRC01 class Abs. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
